ISAR-REACT 5: Prasugrel Bests Ticagrelor in ACS ISAR-REACT 5: Prasugrel Bests Ticagrelor in ACS

In this ' landmark ' head-to-head trial, 1-year survival free of MI or stroke was better in patients with ACS who received prasugrel rather than ticagrelor -- contrary to the researchers ' hypothesis.Medscape Medical News

Source: Medscape Medical News Headlines - September 2, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news